Nemluvio was well tolerated and showed sustained improvements in moderate to severe prurigo nodularis during a 2-year ...

Routine SLNB may be used to predict tumor invasion levels and SLN metastasis in patients with EMPD who do not have enlarged lymph nodes.

Cambridge Investment Research Advisors Inc. boosted its holdings in Journey Medical Corporation (NASDAQ:DERM – Free Report) ...

A research team has developed a diagnostic system that uses artificial intelligence (AI) to accurately identify the type of ...

A 35-year-old man presents with a chief complaint of purple discoloration of his toes and associated skin lesions that have ...

A research team led by Haruyo Yamamoto, Chisa Nakashima, and Atsushi Otsuka from Department of Dermatology, Kindai University Faculty of Medicine, in collaboration with the Faculty of Engineering at ...

Your brain and skin are interconnected—and when a disorder affects both, treatment must involve a multidisciplinary approach.

Dr. Vlada Groysman of Cahaba Dermatology is the ONLY vulvar dermatologist in the Southeast. Get to know this trailblazing ...

Learn more about the Academy’s payer advocacy efforts.

Was that mole always there? Photograph, track, and identify marks with these apps before you head to your dermatologist.

Journey Medical (DERM) announced that a data analysis from two Phase 3 multicenter clinical trials, evaluating Emrosi for the treatment of moderate-to-severe papulopustular rosacea in adults will be ...

Nemolizumab significantly and safely improved itch and skin lesions for up to 2 years in patients with moderate to severe prurigo nodularis.